Ernexa Therapeutics Inc. Assets, Fair Value Disclosure
Ernexa Therapeutics Inc. (ERNA) had Assets, Fair Value Disclosure of $0 as of 2021-12-31, per its 10-K/A filed 2022-07-01.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures
us-gaap:AssetsFairValueDisclosure · last filed 2022-07-01
- 2021-12-31: Assets, Fair Value Disclosure $0.00.
- 2020-12-31: Assets, Fair Value Disclosure $0.00.
| Period end | Assets, Fair Value Disclosure |
|---|---|
| 2021-12-31 | $0.00 10-K/A · filed 2022-07-01 |
| 2020-12-31 | $0.00 10-K/A · filed 2022-07-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |